MyDosageBeta
Scan
GLP-1 receptor agonist

Liraglutide

Daily GLP-1 analogue, first-in-class for chronic weight management. Older and shorter-acting than semaglutide.

Human RCT · t½ ~13 h · 0.6–3.0 mg/day

Start with a product

Pick what you have. We'll guide the rest.

Schedule, what to expect, side-effects to watch — built around your exact product.

Scan a productAdd manually
AHuman RCT evidenceHuman RCTGLP-1 receptor agonist

Also: Saxenda · Victoza

Daily GLP-1 analogue, first-in-class for chronic weight management. Older and shorter-acting than semaglutide.

Scientific Consensus Engine

Evidence Intelligence Score™

Heuristic — no indexed evidence yet
6.5/ 10
Overall confidence
Moderate
Outlook
Moderate
Evidence maturity
  1. Preclinical
  2. Pilot human
  3. RCT← current
  4. Multi-RCT
  5. Meta-analysis

Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.

Eight-dimension breakdown
  1. Human evidence
    Weight of RCT and observational data
    8.8
  2. Safety maturity
    Follow-up depth and adverse-event signal
    6.5
  3. Mechanism confidence
    Pathway specificity and clarity
    6.4
  4. Clinical readiness
    Distance to physician-prescribable use
    7.8
  5. Research momentum
    Recency of indexed clinical evidence
    5.0
  6. Study consistency
    Effect direction across cohorts
    4.4
  7. Long-term data
    Follow-up beyond initial trial windows
    5.4
  8. Translational confidence
    Animal → human signal preservation
    7.7
Strongest supported claim

Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.

Weakest / unclear

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Major unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Scientific outlook

Outlook: maturing. Expect the consensus to harden as multi-site replications publish.

Reported outcomes · graded
Weight management
Agrade
8.0
Mechanism
GLP-1 receptor agonist; albumin-binding extends half-life relative to native GLP-1.
Reported uses
Citations
What we don't know yet
  • —Long-term safety beyond reported study durations.
  • —Effect size in populations under-represented in the cited trials.
  • —Interactions with concomitant medications outside listed contraindications.

We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.

Editorial team
Independent · No affiliate revenue
Reviewed quarterly
Brands carrying this peptide

2 brands across three tiers.

Medicine

2 brands

Regulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.